Table 6 Baseline characteristics per dosage used for each group
Group A* | Fixed prophylactic dose (n = 26) | Higher prophylactic (weight/anti-Xa-adjusted) (n = 16) | Full treatment dose (n = 34) | p-value | |
Mean age at enrolment | 32.23 ± 4.39, 32, 30–35 | 33.94 ± 3.94, 32.5, 31–37 | 33.06 ± 4.31, 33, 30–36 | 0.5021 | |
BMI | 23.02 ± 2.85, 22.86, 20.76–23.88 | 26.03 ± 3.62, 25.37, 23.66–28.65 | 25.98 ± 5.01, 24.45, 21.88–29.38 | 0.0101 | |
Mean duration of LMWH use | 8.82 ± 1.46, 9.5, 9–9.5 | 9.17 ± 1.25, 9, 9–10 | 8.34 ± 1.98, 9, 8–9.5 | 0.1560 | |
No of foetuses at the observed gestation | 1.04 ± 0.2, 1, 1–1 | 1.06 ± 0.25, 1, 1–1 | 1.03 ± 0.17, 1, 1–1 | 0.8560 | |
High risk thrombophilia (Positives,% in group) | 4, 15.38% | 3, 18.75% | 12, 35.29% | 0.1706 | |
APA status (successful tests N = 54) (N positive/N negative, % in treatment type) | 7/22, 31.82% | 2/11, 18.18% | 7/21, 33.33% | 0.6440 | |
History of VTE | |||||
Unprovoked | 6 | 5 | 8 | 0.4238 | |
Provoked by combined oral contraceptives | 20 | 11 | 26 | ||
Concomitant ASA use (Positives,% in group) | 3, 11.54% | 3, 18.75% | 5, 14.71% | 0.8111 | |
Group B* | Fixed dose prophylactic (n = 262) | Higher prophylactic (n = 144) | Therapeutic (n = 39) | p-value | |
Mean age at enrolment | 33.43 ± 4.43, 34, 31–36 | 34.08 ± 4.75, 34, 31–37 | 32.31 ± 4.92, 33, 29–36 | 0.2326 | |
BMI | 23.58 ± 3.19, 23.18, 21.67–24.46 | 25.45 ± 4.6, 24.94, 21.87–28.28 | 25.77 ± 4.22, 24.57, 23.18–27.18 | <.0001 | |
No of foetuses at the observed gestation | 1.02 ± 0.16, 1, 1–1 | 1.04 ± 0.2, 1, 1–1 | 1.03 ± 0.16, 1, 1–1 | 0.2657 | |
Mean duration of LMWH use | 8.51 ± 1.53, 9, 8–9 | 9.09 ± 0.87, 9, 9–10 | 8.86 ± 0.83, 9, 9–9.5 | 0.0001 | |
High risk thrombophilia (Positives,% in group) | 23, 8.78% | 18, 12.50% | 4, 10.26% | 0.4924 | |
APA status (successful tests N = 196) (N positive/N negative, % in treatment type) | 30/126, 23.81% | 17/55, 30.91% | 10/15, 66.67% | 0.0024 | |
History of early pregnancy loss (Positives,% in group) | 228, 87.02% | 132, 91.67% | 36, 92.31% | 0.7271 | |
History of IUGR (Positives,% in group) | 5, 1.91% | 4, 2.78% | 1, 2.56% | ||
History of intrauteral fetal death (Positives,% in group) | 20, 7.63% | 6, 4.17% | 2, 5.13% | ||
History of pre-eclampsia/eclampsia | 8, 3.05% | 2, 1.39% | 0 | ||
History of placenta abruption/preterm delivery (Positives,% in group) | 1, 0.38% | 0 | 0 | ||
Concomitant ASA use (Positives,% in group) | 34, 12.98% | 41, 28.47% | 6, 15.38% | 0.0005 | |
Group C* | Fixed dose prophylactic (n = 66) | Higher prophylactic (n = 51) | Therapeutic (n = 15) | p-value | |
Mean age at enrolment | 36.18 ± 4.95, 36, 34–39 | 38.55 ± 5.01, 38, 35–42 | 36.87 ± 5.3, 37, 32–42 | 0.0559 | |
BMI | 23.71 ± 3.71, 22.86, 21.05–24.978 | 25.48 ± 3.87, 24.83, 23.03–28.604765 | 26.34 ± 2.27, 26.3, 24.91–27.89 | 0.0003 | |
No of foetuses at the observed gestation | 1.15 ± 0.36, 1, 1–1 | 1.27 ± 0.49, 1, 1–2 | 1.47 ± 0.52, 1, 1–2 | 0.0278 | |
Mean duration of LMWH use | 8.18 ± 2.12, 9, 8.5–9 | 9.23 ± 1, 9, 9–10 | 9.17 ± 0.45, 9, 9–9.5 | 0.0007 | |
High risk thrombophilia (Positives,% in group) | 5, 7.58% | 5, 9.80% | 3, 20.00% | 0.3456 | |
APA status (successful tests N = 59) (N positive/N negative, % in treatment type) | 10/33, 30.30% | 6/20, 30.00% | 0/6, 0% | 0.2885 | |
Concomitant ASA use (Positives,% in group) | 18, 27.27% | 20, 39.22% | 2, 13.33% | 0.1194 | |
Group D* | Fixed dose prophylactic (n = 86) | Higher prophylactic (n = 61) | Therapeutic (n = 18) | p-value | |
Mean age at enrolment | 31.33 ± 4.38, 31, 29–34 | 33.49 ± 4.35, 34, 31–36 | 34.61 ± 3.42, 34.5, 32–37 | 0.0007 | |
BMI | 23.68 ± 2.68, 23.57, 21.87–25.65 | 24.09 ± 4.26, 23.12, 21.21–25.34 | 29.3 ± 7.21, 27.59, 24.51–33.13 | 0.0004 | |
No of foetuses at the observed gestation | 1.02 ± 0.15, 1, 1–1 | 1.07 ± 0.25, 1, 1–1 | 1.06 ± 0.24, 1, 1–1 | 0.4385 | |
Mean duration of LMWH use | 8.15 ± 1.63, 9, 8–9 | 8.6 ± 1.37, 9, 9–9 | 8.06 ± 2.17, 9, 9–9 | 0.0521 | |
High risk thrombophilia (Positives,% in group) | 7, 8.14% | 7, 11.48% | 3, 16.67% | 0.5181 | |
APA status (successful tests N = 54) (N positive/N negative, % in treatment type) | 3/26, 11.54% | 8/26, 30.77% | 0/2, 0% | 0.1742 | |
Family History of VTE (Positives,% in group) | 48, 55.81% | 21, 34.43% | 4, 22.22% | 0.0003 | |
Asymptomatic Thrombophilia | 22, 25.58% | 21, 34.43% | 2, 11.11% | ||
Increased resistance in uterine arteries (Positives,% in group) | 2, 2.33% | 0 | 0 | ||
Reasons not specified (Positives,% in group) | 14, 16.28% | 19, 31.15% | 12, 66.67% | ||
Concomitant ASA use (Positives,% in group) | 7, 8.14% | 13, 21.31% | 0 | 0.0136 | |